Interethnic differences in population prevalence of the HLA-B*1502 allele are shown below.
These data are crucial in preventing carbamazepine-induced Stevens-Johnson Symdrome and Toxic Epidermal Necrolysis.
Patients with HLA-B*1502 alleles face a highly increased risk of developing Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment (Leckband et al. 2013).
In the map below data from the allelefrequencies.net are presented.
Color scheme:
|
no data available |
|
|
prevalence below 1 % *) |
|
|
prevalence between 1 and 5 % *) |
|
|
prevalence above 5 % *) |
*) Click country on map to view details
